Background: Kanglaite (KLT) injection, a kind of Chinese medicine, is considered a promising complementary therapeutic option for malignant cancer treatment. This study aimed to systematically investigate the efficacy and safety of the combination of KLT injection and radiochemotherapy for the treatment of advanced pancreatic cancer (PC).
Introduction
Pancreatic cancer (PC) represents the seventh leading cause of cancer-related deaths and caused 432,242 deaths worldwide in 2018. [1, 2] Currently, the incidence of PC has significantly increased, with about 460,000 new cases every year. [1, 2] China is at a high-risk; PC-related deaths in China account for about 20% in the world. [3] PC is a fatal disease with high mortality and poor prognosis. The median overall survival (OS) of patients with advanced PC is 4 to 6 months and the 5-year OS rate <10%. [4, 5] Despite the improvements in the past decades, the therapeutic effect of current conventional treatments, including radiotherapy and chemotherapy, for advanced PC remains unsatisfactory. [4, 5] Therefore, effective treatment strategies are required.
Traditional Chinese medicine has an extensive history and has been widely used as an effective adjuvant drug for cancer treatment. [6, 7] Kanglaite (KLT) injection is an extract from Coix lacryma-jobi seed whose main active ingredient is a triglyceride containing 4 types of fatty acids (Fig. 1 ). [5, [8] [9] [10] In 1997, KLT injection was formally approved by the Ministry of Health of China for the treatment of malignancies such as PC, lung cancer, gastric cancer, and breast cancer. [5, [11] [12] [13] Over millions cancer patients in more than 2000 hospitals in China have been treated with KLT. [5] Moreover, KLT has shown good efficacy in the US and is also the first traditional Chinese medicine approved by the US Food and Drug Administration (FDA) to carry out clinical trials in the United States. [14] Researches showed that KLT could effectively reverse multiple-drug resistance in cancer cells and enhance the sensitivity of tumor cells to chemotherapeutic drugs. [10, [14] [15] [16] Many in vitro studies have shown that KLT can block the G2/M transition and reduce mitotic divisions, thereby suppressing tumor cell proliferation. KLT also inhibits the invasion of cancer cells and migration induced by tumor necrosis factor a. [17] [18] [19] [20] In addition, it can induce cancer cell apoptosis through the activation of proapoptotic factors, such as p53, Fas, and caspase-3. [15, 21] Several studies indicated that radiochemotherapy combined with KLT injection is more effective for the treatment of advanced PC than radiochemotherapy alone. [5, 22] Despite intensive clinical studies, the efficacy and safety of the combination of KLT injection and radiochemotherapy have not been systematically evaluated. In this study, we conducted a meta-analysis to investigate the efficacy and safety of the combination of KLT injection and radiochemotherapy compared with radiochemotherapy alone in advanced PC (Fig. 1 ). This could provide a basis for the design of future clinical trials.
Materials and methods
This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines and Cochrane Handbook. The ethical approval and patient consent are not required because this study was a metaanalysis.
Search strategy and selection criteria
Original articles were searched across 8 electronic databases, including Cochrane Library, Web of Science, PubMed, Embase, China National Knowledge Infrastructure (CNKI), Chinese Biological Medicine Database (CBM), Wanfang database and Chinese Scientific Journal Database (VIP) before October 2018. The search terms were: "Kanglaite injection" or "coix seed injection" combined with "pancreatic carcinoma" or "pancreatic cancer."
The inclusion criteria were:
(1) controlled trials conducted with patients with advanced PC;
(2) studies comparing the clinical outcomes of radiochemotherapy and KLT injection adjuvant therapy (experimental group) with radiochemotherapy alone (control group); and (3) studies that included >30 patients with PC.
The exclusion criteria were:
(1) non-contrast articles, case studies, and review articles; and (2) patients with mixed malignancies.
Data extraction and quality assessment
Data were extracted by 2 investigators (Liu JL and Yu LB) independently; any disagreement was adjudicated by a third reviewer (Ding W). The following data were extracted:
(1) name of the first author;
(2) year of publication;
(3) study location; (4) tumor stage; (5) Karnofsky Performance Score (KPS); (6) Eastern°Cooperative°Oncology°Group (ECOG) Score; (7) number of cases; (8) age of the patients; (9) study parameters; (10) therapeutic regimens; (11) enrollment period; and (12) dosage of KLT injection.
The trial quality was evaluated according to Cochrane Handbook. [23] 
Outcome definitions
Clinical responses included treatment efficacy, quality of life (QoL), and adverse events. Treatment efficacy was assessed in were used to assess heterogeneity between studies; if P >.1 or I 2 < 50%, the fixed effects model was used for the meta-analysis; otherwise, the random-effects model was used according to the DerSimonian and Laird method. [24] The presence of publication bias was investigated using the Egger test and funnel plots. A 2tailed P value <.05 was considered statistically significant. Treatment effects were mainly represented by odds ratio (OR) with a 95% confidence interval (CI). Sensitivity analysis was conducted to evaluate the impact of different therapeutic regimens, KLT injection dosages, sample sizes, and type of research on the clinical efficacy of the combination of KLT injection and radiochemotherapy.
Results

Search results
A total of 237 publications were identified after the initial search. Of these, 172 publications were excluded due to duplication. After title and abstract review, 38 articles were further excluded because they did not include clinical trials (n = 31) or were unrelated studies (n = 7). Of the remaining 27 publications, studies that did not include a control group (n = 3), meta-analyses (n = 3), and studies with insufficient data (n = 5) were excluded. Finally, 16 trials [5, 22, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] involving 960 patients with advanced PC were included in the final analysis ( Fig. 2 ).
Patient characteristics
Most of the included studies were performed in different medical centers in China; [22, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] 1 trial was conducted in the US. [5] In total, 494 patients with advanced PC were treated with radiochemotherapy in combination with KLT injection adjuvant therapy, while 466 patients were treated with radiochemotherapy alone. Study and patient characteristics are shown in Table 1 and Table 2 . 
Quality assessment
The assessment of the risk of bias is shown in Figure 3 . Fifteen studies [5, 22, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] 37, 38] were determined as low risk and the remaining 1 study [36] was not a true randomized controlled trial. Most included trials did not provide a clear description of performance and detection risks. One open-label study [5] was considered as high performance and detection risk. The attrition risks of the selected studies were low; 1 study [22] was categorized as high risk due to the absence of follow-up and the risk of 2 studies [25, 32] was considered unclear owing to selective reporting.
Efficacy assessments
As shown in Figures 4 and 5, and Table 3 , the pooled results showed that patients who underwent combination therapy had significantly improved 1-year OS (OR = 2.58, 95% CI = 1.12-5.93, P = .03), CR (OR = 2.28, 95% CI = 1.22-4.24, P = .010), PR (OR = 1.75, 95% CI = 1.27-2.40, P = .0006), ORR (OR = 2.16, 95% CI = 1.58-2.94, P <.00001) and DCR (OR = 2.50, 95% CI = 1.84-3.38, P <.00001) and significantly decreased PD (OR = 0.40, 95% CI = 0.29-0.55, P <.00001) compared with those who received radiochemotherapy alone. In contrast, SD and 2-years OS rates of patients who received combination therapy were not significantly different from patients those who received radiochemotherapy alone (SD: OR = 1.17, 95% CI = 0.87-1.57, P = .30; 2 years OS: OR = 1.59, 95% CI = 0.49-5.15, P = .44). Fixed-effect models were used to analyze OR rate because of low heterogeneity. [33] China ND ECOG2 21/23 ND ND ORR, DCR, AE Yao XJ [2015] [34] China [36] China ND ND 40/40 74.2±5.9 (mean) 75.7±5.6 (mean) ORR, DCR, AE Zhu Q [2013] [37] China ND KPS (60-90) 27/28 39-72 37-70 ORR, DCR, QoL, AE Zou WB [2016] [38] China ND ND 30/30 ND ND ORR, DCR, QoL, AE 
Detection of tumor markers
Two clinical trials [22, 29] evaluated tumor markers in patients with PC patient between the 2 groups. As shown in Figure 6 , the levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 199 (CA199) were significantly decreased after the combination therapy compared with radiochemotherapy alone (CEA, OR = -4.49, CI = -6.57 to -2.40, P <.0001; CA199, OR = -103.05, CI = -127.42 to -78.67, P <.00001).
QoL assessment
We found that QoL of patients who received combination treatment was significantly better than that of the control group, indicated by significantly increased QIR, PRR, and WGR ( Fig. 7 , QIR: OR = 3.68, 95% CI = 2.36-5.75, P <.00001; PRR: OR = 3.70, 95% CI = 2.23-6.14, P <.00001; WGR: OR = 3.69, 95% CI = 2.22-6.13, P <.00001).
Adverse events assessment
As shown in Table 4 and Supplementary Figure 1 , and anorexia (OR = 0.19, 95% CI = 0.00-9.80, P = .41) did not differ significantly between the 2 groups.
Publication bias
Publication bias was assessed visually by funnel plots and quantified using Egger's test and Begg regression test. As shown in Figure 8 , no significant publication bias for ORR (Begg = 0.533; Egger = 0.395) and DCR (Begg = 0.843; Egger = 0.981) was observed in these analyses, which confirmed the reliability of our primary outcomes.
Sensitivity analysis
We conducted a subgroup analysis to explore the source of heterogeneity in ORR and DCR with respect to therapeutic regimen, KLT injection dose, sample size, and type of study. As shown in Table 5 , there was no significant difference between different doses of KLT injection, sample size, and types of studies. Moreover, in terms of ORR index, KLT injection combined with S-1/Gemcitabine + 3-dimensional conformal radiotherapy regimen was found to be more effective for PC treatment.
Discussion
The limitations of the current radiochemotherapeutic treatment for malignancies include drug resistance and toxic side effects. Clinicians have been exploring complementary and alternative treatments to improve survival time or QoL of patients and to reduce side effects caused by radiochemotherapy. [39] [40] [41] Traditional Chinese medicine, particularly KLT injection, has been used as an adjuvant therapy for decades. Several studies have been reported that the addition of KLT injection could be beneficial to patients with advanced PC. Even though there was statistical analysis of published clinical trials, the exact therapeutic effects were still not systematically evaluated because of small sample size and different protocols used in the studies. Therefore, in this study, we conducted a wide range of online search and applied strict inclusion and exclusion criteria to derive a clear and systematic conclusion. [22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] 414 [22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Fixed 0 .93 2.28 1. 22-4.24 .010 PR 416 [22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] 414 [22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Fixed 0 1.00 1.75 1. 27-2.40 .0006 SD 416 [22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] 414 [22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Fixed 0 .69 1.17 0.87-1.57 .30 PD 416 [22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] 414 [22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Fixed 0 1.00 0.40 0.29-0.55 <.00001 ORR 461 [5, 22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] 436 [5, 22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Fixed 0 .99 2.16 1.58-2.94 <.00001 DCR 461 [5, 22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] 436 [5, 22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Fixed 0 1.00 2.50 1.84-3.38 <.00001
Control group: radiochemotherapy alone group; experimental group: radiochemotherapy and kanglaite injection combined group. CR = complete response, DCR = disease control rate, ORR = overall response rate, PD = progressive disease, PR = partial response, SD = stable disease. Our meta-analysis revealed that a combination of radiochemotherapy and KLT injection was more effective for the treatment of PC compared with radiochemotherapy alone. Patients treated with combined therapy exhibited significantly prolonged 1-year OS, broadly increased ORR and DCR (P <.05), and significantly improved QoL. Specific molecular markers including CEA and CA199 are commonly used to predict the recurrence, metastasis, and prognosis of PC after treatment. [42, 43] Our analysis showed that both CEA and CA199 were differentially decreased after radiochemotherapy and KLT injection combination treatment. These results indicated that using KLT injection could improve the curative effects of radiochemotherapy for advanced PC.
Our analysis showed that some of the adverse events caused by radiochemotherapy, including gastrointestinal side effects, nephrotoxicity, leukopenia, thrombocytopenia, and myelosuppression, were alleviated with KLT injection combination therapy. Therefore, KLT injection may be a well-tolerated treatment for PC and can effectively alleviate partial adverse events associated with radiochemotherapy.
The analysis on therapeutic effects may be influenced by several factors. In our study, no difference was found between different drug forms of KLT injection, sample size, and type of research types. In terms of ORR, KLT injection combined with S-1/ Gemcitabine+ 3-dimensional conformal radiotherapy regimen was more effective for PC treatment. However, studies on the There are some limitations in this study. First, there was significant heterogeneity among the included trials, which may be due to variation in tumor stage and age of the patients, year of publication, and duration of treatment. However, based on currently available literature, there are insufficient data to perform further statistical analysis to evaluate the correlation. Second, as an important Chinese herbal injection, KLT was mainly used in China; this may lead to an unavoidable regional bias and subsequently, influence the clinical application of KLT injection worldwide. Third, smoking history and other diseases may have an impact on CA 199. [44] It is advisable to collect the smoking history and past medical history of the patients to strengthen the rationale. However, our data were extracted from publications where this information was not sufficiently provid-ed. Therefore, based on currently available literature, there are insufficient data to perform a statistical analysis to evaluate the correlation. We will keep paying close attention to this concern in our later studies. Finally, as the sources of our data were published articles instead of raw records of clinical trials, analytical bias could exist.
Conclusion
In summary, this meta-analysis indicated that the combination of KLT injection and radiochemotherapy was effective in treating patients with advanced PC. Clinical application of KLT injection not only improved the therapeutic effects of radiochemotherapy but also alleviated the side effects caused by radiochemotherapy. However, the long-term efficacy of KLT injection-mediate adjuvant therapy for advanced PC requires further investigation through clinical trials. Gastrointestinal adverse effects 298 [22, [25] [26] [27] [28] [29] [34] [35] [36] 38] 296 [22, [25] [26] [27] [28] [29] [34] [35] [36] 38] Fixed 0 .76 0.68 0.47-0.98 .04 Hepatotoxicity 213 [26, 27, 30, [34] [35] [36] 38] 213 [26, 27, 30, [34] [35] [36] 38] Fixed 0 .98 0.78 0.40-1.54 .47 Nephrotoxicity 213 [26, 27, 30, [34] [35] [36] 38] 213 [26, 27, 30, [34] [35] [36] 38] Fixed 0 .84 0.28 0.12-0.66 .004 Neurotoxicity 159 [26, 27, 34, 36, 38] 157 [26, 27, 34, 36, 38] Fixed 0 .75 0.80 0.42-1.51 .49 Leukopenia 101 [28, 30, 31, 33] 102 [28, 30, 31, 33] Random 51 .10 0.30 0.12-0.77 .01 Thrombocytopenia 154 [5, 28, 30, 31, 33] 129 [5, 28, 30, 31, 33] Fixed 44 .13 0.40 0.23-0.69 .001 Anemia 123 [5, 28, 31, 33] 95 [5, 28, 31, 33] Random 78 .004 0.46 0.12-1.70 .24 Myelosuppression 152 [26, 27, [34] [35] [36] 149 [26, 27, [34] [35] [36] Fixed 0 .63 0.54 0.30-0.95 .03 Nausea 107 [5, 30, 33] 82 [5, 30, 33] Fixed 0 .77 0.89 0.49-1.63 .70 Vomiting 122 [5, 30, 31, 33] 97 [5, 30, 31, 33] Random 74 .009 0.45 0.12-1.68 .24 Diarrhea 91 [5, 31, 33] 63 [5, 31, 33] Fixed 21 .28 0.67 0.33-1.34 .25 Rash 91 [5, 31, 35] 64 [5, 31, 35] Fixed 0 .57 0.95 0.37-2.45 .92 Weak 76 [5, 33] 48 [5, 33] Fixed 0 .67 1.10 0.46-2.61 .84 Fatigue 76 [5, 35] 49 [5, 35] Fixed 0 .95 0.91 0.42-1.97 .81 Anorexia 68 [5, 31] 42 [5, 31] Random 84 .01 0.19 0.00-9.80 .41
Control group: radiochemotherapy alone group; experimental group: radiochemotherapy and kanglaite injection combined group. [26, 27, 31, 33, 34, 36, 38] 193 [26, 27, 31, 33, 34, 36, 38] Fixed 0 0.99 2.11 1.31-3.39 0.002 KLT injection+Gemcitabine 77 [5, 28] 54 [5, 28] Fixed 0 0.46 2.04 0.70-5.94 0.19 KLT injection+Gemcitabine+3-DCRT 105 [22, 29, 32] 106 [22, 29, 32] Fixed 0 0.40 2.61 1.49-4.57 0.0008 Dosage of KLT injection >200mL/day 324 [5, 26, 27, 30, 31, [33] [34] [35] [36] [37] [38] 298 [5, 26, 27, 30, 31, [33] [34] [35] [36] [37] [38] Fixed 0 1.00 2.03 1.38-3.01 0.0004 100mL/day 137 [22, 28, 29, 32] 138 [22, 28, 29, 32] Fixed 0 0.49 2.39 1.43-3.98 0.0009 Study sample size ≥60 300 [5, 26, [28] [29] [30] 34, 36, 38] 280 [5, 26, [28] [29] [30] 34, 36, 38] Fixed 0 0.89 2.40 1.63-3.52 <0.00001 <60 161 [22, 27, [31] [32] [33] 35, 37] 156 [22, 27, [31] [32] [33] 35, 37] Fixed 0 1.00 1.79 1.03-2.99 0.04 Type of control trials RCT 421 [5, 22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] 37, 38] 396 [5, 22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] 37, 38] Fixed 0 0.99 2.09 1.51-2.89 <0.00001 Overall 461 [5, 22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] 436 [5, 22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Fixed 0 0.99 2.16 1.58-2.94 <0.00001 DCR Therapeutic regimen KLT injection+S-1 197 [26, 27, 31, 33, 34, 36, 38] 193 [26, 27, 31, 33, 34, 36, 38] Fixed 0 0.93 2.46 1.61-3.77 <0.0001 KLT injection+Gemcitabine 77 [5, 28] 54 [5, 28] Fixed 0 0.42 2.93 1.35-6.39 0.007 KLT injection+Gemcitabine+3-DCRT 105 [22, 29, 32] 106 [22, 29, 32] Fixed 0 0.84 2.35 1.16-4.79 0.02 Dosage of KLT injection >200mL/day 324 [5, 26, 27, 30, 31, [33] [34] [35] [36] [37] [38] 298 [5, 26, 27, 30, 31, [33] [34] [35] [36] [37] [38] Fixed 0 1.00 2.41 1.70-3.43 <0.00001 100mL/day 137 [22, 28, 29, 32] 138 [22, 28, 29, 32] Fixed 0 0.79 2.75 1.50-5.04 0.001 Study sample size ≥60 300 [5, 26, [28] [29] [30] 34, 36, 38] 280 [5, 26, [28] [29] [30] 34, 36, 38] Fixed 0 0.97 2.68 1.84-3.90 <0.00001 <60 161 [22, 27, [31] [32] [33] 35, 37] 156 [22, 27, [31] [32] [33] 35, 37] Fixed 0 0.98 2.18 1.30-3.66 0.003 Type of control trials RCT 421 [5, 22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] 37, 38] 396 [5, 22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] 37, 38] Fixed 0 1.00 2.39 1.74-3.30 <0.00001 Overall 461 [5, 22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] 436 [5, 22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Fixed 0 1.00 2.50 1.84-3.38 <0.00001 
